PP 1420

Imperial College London · Phase 1 active Small molecule

At a glance

Generic name	PP 1420
Also known as	PP 1420 pancreatic polypeptide analog
Sponsor	Imperial College London
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability and Efficacy Study of PP1420 in HV (PHASE1, PHASE2)
A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PP 1420 CI brief — competitive landscape report
PP 1420 updates RSS · CI watch RSS
Imperial College London portfolio CI